New and Improved Service

Posted:
26
August 2004

Claire Tucker, Head of Sales and Marketing

Richmond Pharmacology's (RPL's) highly successful business team has recently undergone a re-organisation to enhance the outstanding service we provide to our valued clients.Claire Tucker, Head of Sales and Marketing, commented:‘Our improved structure includes dedicated business Account Managers, specifically allocated to a particular client and able to guide them through the initial stages of introduction and study specific contract negotiation. These Account Managers continue to be at hand throughout as an additional point of contact until the study has reached its completion. As usual, our proficient Clinical Project Managers will co-ordinate the smooth day-to-day running of the study and will continue to work on a one to one basis with client teams. I am delighted with the new structure and the impact this is already having on our clients.’This framework has been introduced to ensure even better communication from initial contact through to close out, maintaining RPL's supportive and personal approach.Providing additional support for Phase II is our dedicated Phase II Department, see more on our patient studies page.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more